Ongoing Laboratory Research

GLP-1 Agonists & Longevity

Welcome to our dedicated space for the latest advancements in GLP-1 studies. Our clinical laboratory is dedicated to studying GLP-1 medications — the same class of drugs behind treatments like Ozempic and Mounjaro — to better understand their far-reaching effects on human health. While these therapies are best known for managing blood sugar and promoting weight loss, our work explores their broader potential across the body, including protecting the heart, improving kidney function, supporting brain health and potentially slowing neurodegenerative diseases like Alzheimer's and Parkinson's, reducing liver inflammation, and even influencing addiction and reward behavior. Through active clinical studies and long-term outcome research, our goal is to understand not just how these medications work, but how they can be used most effectively to improve and extend the lives of our patients.

Latest GLP-1 Updates

METABOLIC SCIENCE

What GLP-1 Actually Is — The Physiology Behind the Most Talked-About Hormone in Medicine

Science behind how the Incretin hormone released from intestinal L-cells enhances glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety, and myriad of other functions

Read Update

DIABETES

The Drug Class That's Rewriting What We Thought Was Possible With Diabetes

New lab data indicates that GLP-1 signaling significantly enhances insulin secretion, while preserving pancreatic beta-cell function and reduces cardiovascular risks

Read Update

WEIGHT REGULATION

GLP-1 and Obesity: Rethinking Weight Regulation

An analysis of how GLP-1 therapy is shifting medical understanding from willpower-based weight loss to biological regulation.

Read Update

HEART HEALTH

Cardiac Resilience and Inflammation

Exploring the role of GLP-1 in reducing systemic vascular inflammation and its long-term impact on cardiovasvular resilience.

Read Update

BRAIN HEALTH

GLP-1 Impact on Synaptic Plasticity

Observations from recent trials suggest that GLP-1 therapy may actively support the repair of synaptic connections in early neurodegeneration.

Read Update

KIDNEY DISEASE

Protective Mechanisms in Renal Health

New longitudinal studies reveal how GLP-1 receptor activation significantly reduces biomarkers of kidney stress in chronic patients.

Read Update

LIVER HEALTH

Managing Hepatic Steatosis with GLP-1

Phase II data indicates promising outcomes in reversing fat accumulation in the liver through specialized GLP-1 receptor activation.

Read Update

NUTRITION SCIENCE

Protein Partitioning During GLP-1 Therapy

New clinical guidelines on nutrient intake and macro-partitioning to optimize results and minimize side effects in long-term therapy.

Read Update

FUTURE OUTLOOK

Next-gen Incretin Mimetics Roadmap

A look into the pipeline of upcoming molecules that aim to refine incretin signaling for even more targeted health interventions.

Read Update

LONGEVITY STRATEGY

Micro-Dosing GLP-1: A New Longevity Frontier

Exploration of sub-therapeutic GLP-1 levels and their impact on systemic inflammation and cellular senescence markers.

SAFETY DATA

GLP-1 Safety and Side Effects: What the Data Really Shows

A comprehensive review of the long-term safety profile of GLP-1 agonists based on meta-analysis of recent clinical outcomes.

Read Update

NEUROBEHAVIOR

GLP-1 and Addictions: Exploring Neurobehavioral Pathways

Emerging studies on how GLP-1 influences dopamine-driven reward centers, potentially offering new avenues for addiction treatment.

Read Update